June 2003

Contents

Editorial

• Volume 4 Number 5 June 2003

Conference reports

• 9th Annual British HIV Association Conference (BHIVA), 24-26 April 2003, Manchester

• UK 2003 audit and national standards of care

• Outline of changes to UK 2003 guidelines for treating HIV in adults

• Gender differences in rates and reasons for stopping treatment

• Maternal health, transmission and fertility

• Women: sexual function and relationships

• Paediatrics: neurological and developmental outcomes

• The impact of migration, race and ethnic diversity on healthcare delivery and clinical outcomes in the UK

• High levels of gout may be linked to HAART

Antiretrovirals

• New 625mg formulations of nelfinavir

• Lopinavir suitable for TDM

Treatment access

• Global Fund requires ‘significant’ new money

• Commentary: a crisis the Board must confront

• ‘Fund the Fund’ launches campaign pack

• Senate approves Bush’s $15 billion international AIDS bill

• GSK halves drug prices to 63 countries

• Shareholders target PepsiCo over care for its employees in Africa

• Burkina Faso to purchase generic drugs from Indian company

• South Africa fails to accept $41 million from Global Fund

• UK gives £15.7m to Burmese HIV project

• Death of South African AIDS activist fuels anger

Diagnostics

• Three-minute HIV test wins approval in China and the USA

• New TB blood test shows promise

Side effects

• Tenofovir side effects

• HIV-positive patients sustain acute myocardial infarction at a young age and have a benign in-hospital course

• Cardiovascular and cerebrovascular events in patients treated for HIV infection

• Severe hepatotoxicity during ART: incidence, liver histology, and outcome

• Peripheral neuropathy in HIV disease: Lactate levels may help determine if nucleoside toxicity is a contributing factor

Lipodystrophy and metabolic complications

• Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women

Coinfections and complications

• Anabolic steroid oxymetholone reduces wasting among HIV patients on HAART

Hepatitis coinfection

• Genotype, enzyme levels, and viral load are clues to hepatitis C virus outcomes

• Adherence and mental side effects during HCV treatment with interferon alfa and ribavirin in psychiatric risk groups

• Key to hepatitis C virus persistence found

• Co-infection: liver transplantation in HIV-positive persons

HIV prevention and transmission

• A case of intraclade HIV-1 superinfection by wild-type virus illustrates the potential to impact disease progression

Vaccines and microbicides

• HIV vaccine symposium: more questions than answers

• Pushing the envelope: a new dawn for the role of antibodies in immune control of HIV?

Other news

• EMEA rejects recombinant Human Growth Hormone for AIDS-related wasting

• England faces soaring sexual infections, warns Adler

• UK campaign to remove Nonoxynol-9 from condoms and lubricants

On the web

• US issues revised TB Guidelines

• Conference abstracts and reports: 4th International Workshop on Clinical Pharmacology of HIV Therapy; 12th Annual Canadian Conference on HIV/AIDS Research

• On-line medical training: IAPAC I-Med Exchange; Nucleoside/Nucleotide Analogue Guide

• Medscape articles

• Newsletters and reports

• Catalogue of FDA approved drug products

PDFs

• Volume 4 Number 5 June 2003 PDF